Loading
A phase 1 trial of PoMA sonodynamic therapy run by Alpheus Medical, Inc., now recruiting.
TMZ + RT + 5-ALA + LIDU SDT System for Newly Diagnosed Butterfly Glioma is a phase 1 interventional study registered as NCT07862647 by Alpheus Medical, Inc., with 30 participants planned, started 2026-10-29, primary completion expected 2027-10-30. Conditions recorded: Glioblastom WHO Grade 4, GBM, bGBM, Butterfly GBM, Bihemispheric GBM, Glioblastoma. Interventions recorded: 5-ALA, Porphyrin Metabolite Activation (PoMA) with LIDU ultrasound.
Shares PoMA sonodynamic therapy, Alpheus Medical and the tag pipeline.
Shares PoMA sonodynamic therapy, Alpheus Medical, Glioma & glioblastoma and the tag pipeline.
Shares Glioma & glioblastoma and the tag pipeline.
Shares Glioma & glioblastoma and the tag pipeline.
Shares Glioma & glioblastoma and the tag pipeline.
Shares Glioma & glioblastoma and the tag pipeline.
Shares Glioma & glioblastoma and the tag pipeline.
Shares Glioma & glioblastoma and the tag pipeline.
Every source this page cites, grouped by who published it. Grouping is read from the web address, not assigned by hand.
A source that has moved or gone is reported by the weekly link check. /audit/